The company will now apply to the FDA for Phase I human clinical trials for BC-819.
Drug development company Biocancell Therapeutics Ltd. (TASE:BICL) reports that preclinical animal trials of its BC-819 drug has been shown effective against ovarian and liver cancer. The company will now apply to the US Food and Drug Administration (FDA) for Phase I human clinical trial to test the drug on these and other cancers.
Biocancell has also released interim results for the preclinical trials of BC-820 and BC-821 cancer treatments. BC-820 was shown to be effective in treating ovarian cancer and BC-821 was shown to be effective in treating bladder cancer. BC-820 and BC-821 are supplementary treatments for BC-819, and are expected to greatly expand the number of patients who can be treated with the company’s drugs.
Three weeks ago, Biocancell reported successful results of its Phase I/IIa clinical trial of BC-819 for the treatment of bladder cancer treatment.
Biocancell rose 9% by midday.
Published by Globes [online], Israel business news - www.globes.co.il - on October 23, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007